Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

• Main Authors: Qiu-Ling Chen, Hao-Ran Yin, Qing-Yu He, Ying Wang
• Format: Article
• Language: English
• Published: Elsevier 2021-06-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: NLRP3; Inflammatory bowel disease; Small molecule inhibitor; Targeted therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332221002274

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing worldwide. Current approved medication for IBD treatment in the clinic mainly includes corticosteroids and neutralization antibodies to pro-inflammatory cytokines. However, drug resistance and severe side effect hinder long-term efficacy of these agents. The NOD-like receptor family pyrin domain containing protein 3 (NLRP3) is exclusively expressed in several inflammatory and autoimmune diseases. Excessive expression, aberrant activation, polymorphism, and gain-of-function mutation of the NLRP3 inflammasome contribute to IBD pathogenesis. In this article, we summarize the regulatory factors to NLRP3, and review recently developed NLRP3 inhibitors and their preclinical and clinical applications in treating inflammatory and autoimmune diseases. We present our views on the therapeutic potential of NLRP3 inhibitors as emerging therapeutic avenue for IBD.